• Clinical Trials - Rectal cancer

    Study Objective Contact
    ACOSOG Z6051: A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection For Rectal Cancer [LCID Study Number: 2009-011] This study is being done to compare two types of surgery currently used for rectal cancer. The two types of surgery are laparoscopic-assisted rectal resection or open rectal resection. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Peter W. Marcello, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar,
    Sherry G. Heldt, RN.
    CALGB/SWOG C80405: A PHASE III TRIAL OF IRINOTECAN/ 5-FU/ LEUCOVORIN OR OXALIPLATIN 5-FU/LEUCOVORIN WITH BEVACIZUMAB, OR CETUXIMAB (C225) OR WITH THE COMBINATION OF BEVACIZUMAB AND CETUXIMAB FOR PATIENTS WITH UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM [LCID Study Number: 2006-081] The purpose of this study is to determine whether newer treatments can improve the outcome of therapy for advanced colorectal cancer and to evaluate the effects (good and bad) of different regimens of chemotherapy and biologic therapy. THIS TUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar.
    ECOG E5204: Intergroup Randomized Phase III Study Of Post-Operative Oxaliplatin 5-Fluorouracil And Leucovorin vs Oxaliplatin 5-Fluorouacil Leucovorin And Bevacizumab For Patients With Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation [LCID Study Number: 2007-034] The purpose of this study is to compare the effects (good and bad) of a combination of chemotherapy drugs, when given with and without a new drug, bevacizumab, after patients with stage II or stage III rectal cancer have had pre-operative chemoradiation. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar,
    Su Aras.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision [LCID Study Number: 2012-066] This protocol compares the effects of standard treatment (chemotherapy and radiation) to chemotherapy and selective use of standard treatment before surgery for rectal cancer. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    NSABP-R-04: A Clinical Trial Comparing PreOperative Radiation Therapy And Capecitabine With Or Without Oxaliplatin With PreOperative Radiation Therapy And Continuous Intravenous Infusion(CVI) Of 5 Fluorouracil(5-FU) With or Without Oxaliplatin In The Treatment Of Patients With Operable Carcinoma Of The Rectum [LCID Study Number: 2004-070] The purpose of this study is to see if taking capecitabine during the weeks of radiation therapy, is as good as the standard treatment with the drug 5-fluorouracil (5-FU) given continuously during the weeks of radiation therapy in patients with operable rectal cancer. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Donna Cossar,
    Sherry G. Heldt, RN.